TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28969626
Drug: AyuFlex1 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AyuFlex1 (250 mg twice daily)
Study: 25277305
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg intravitreal ranibizumab injections
Study: 25277305
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab injections
Study: 16112244
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg once daily for 24 weeks)
Study: 16112244
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg once daily for 24 weeks)
Study: 9129478
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein (MP; 23 g)
Study: 9129478
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein plus potassium bicarbonate (MP+K; 23 g + 23 mmol KHCO3)
Study: 24940942
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG in the morning on the day of colonoscopy
Study: 24940942
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L split doses of PEG
Study: 20215961
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 100 mg
Study: 20215961
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 200 mg
Study: 20215961
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 300 mg
Study: 18358082
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 400 mg
Study: 10418911
Drug: Reduced antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced antigen formulation (dtpa, SmithKline Beecham Biologicals)
Study: 10418911
Drug: Experimental low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental low dose formulation (dtpa-exp; d and t, Michigan Biologic Products Institute)
Study: 2405089
Drug: Controlled-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol 200 mg once daily
Study: 9535211
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with peripheral blood progenitor cell transplantation (PBPCT) after two cycles of conventional chemotherapy (etoposide 500 mg/m2, ifosfamide 4 g/m2, cisplatin 50 mg/m2, epirubicin 50 mg/m2 plus granulocyte colony-stimulating factor 5 microg/kg) followed by high-dose etoposide 1,500 mg/m2, ifosfamide 12 g/m2, carboplatin 750 mg/m2, and epirubicin 150 mg/m2 with PBPCT.
Study: 9535211
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection in stages I to IIIA patients before high-dose chemotherapy.
Study: 7614524
Drug: Extended-release 5-ISMN
Normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release 5-ISMN 120 mg once daily
Study: 7614524
Drug: ISDN 40
Normalized name: ISDN 40 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN 40 mg every 6 hours
Study: 406602
Drug: Verapamil, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 80 mg three times/day
Study: 406602
Drug: Practolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol, 100 mg three times/day
Study: 24033910
Drug: Intraventricular injection
Normalized name: Brineura 150 MG in 5 mL Intraventricular Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular injection of low-dose rtPA
Study: 24033910
Drug: Placebo (intraventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intraventricular injection of normal saline)
Study: 1803995
Drug: Zidovudine 1500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1500 mg daily
Study: 1803995
Drug: Zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 600 mg daily plus acyclovir 4800 mg daily
Study: 1803995
Drug: Zidovudine 1500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1500 mg daily plus acyclovir 4800 mg daily
Study: 1803995
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of zidovudine
Study: 1803995
Drug: Zidovudine with
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine with high-dose acyclovir
Study: 6519349
Drug: Aspirin/Caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/Caffeine combination (800 mg aspirin, 65 mg caffeine)
Study: 19460503
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and low-dose Cyclosporine (EVL)
Study: 770329
Drug: Attenuated rubella
Normalized name: Live attenuated rubella vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated rubella virus vaccine (administered by nose drops or subcutaneous route)
Study: 770329
Drug: Nose drops
Normalized name: Nose Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose drops and subcutaneous route groups
Study: 28768651
Drug: RCE (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCE (60 mg isoflavone aglycones/d and probiotics)
Study: 21914263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no surgical treatment)
Study: 17597267
Drug: Plasmids encoding
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmids encoding type 1 and type 2 E2 administered to mice
Study: 1968000
Drug: Levonorgestrel and
Normalized name: levonorgestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel and ethinyl oestradiol (0.15 mg levonorgestrel and 0.03 mg ethinyl oestradiol)
Study: 1968000
Drug: Desogestrel and
Normalized name: desogestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel and ethinyl oestradiol (0.15 mg desogestrel and 0.03 mg ethinyl oestradiol)
Study: 31577451
Drug: Pioglitazone (a
Normalized name: pioglitazone (as hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (a PPARÎ³ agonist)
Study: 31577451
Drug: PPARÎ³ agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARÎ³ agonists of the TZD-class
Study: 28855352
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (50 mg twice a day for 2 weeks)
Study: 26683252
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment plus exercise and counseling (n = 35)
Study: 24180163
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg)
Study: 8698872
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine
Study: 8610863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intraarticular ketorolac and morphine
Study: 8408733
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg orally)
Study: 4067783
Drug: Lactose (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (Group L)
Study: 26873052
Drug: Supplemental measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental measles vaccine (sMV) administered at median age of 20 months after 1 or 2 doses of primary measles vaccination
Study: 26873052
Drug: Supplemental measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental measles vaccine (sMV) administered at median age of 20 months after 2 doses of primary measles vaccination
Study: 15825029
Drug: gD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gD vaccine with adjuvants (alum and MPL)
Study: 2880218
Drug: Cyclosporin therapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin therapy
Study: 2696550
Drug: Felbinac gel
Normalized name: felbinac
DrugBank: Felbinac (DB07477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbinac gel applied three times daily
Study: 1011296
Drug: Aspartame (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (1.8 g administered three times daily with meals)
Study: 25958714
Drug: TIVA (propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (propofol to reach 8 mcg/ml)
Study: 15184611
Drug: Natalizumab 1
Normalized name: Natalizumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 1 mg/kg
Study: 15184611
Drug: Natalizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (both doses)
Study: 10069551
Drug: Ritanserin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 2.5 mg/day
Study: 10069551
Drug: Ritanserin 5
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 5 mg/day
Study: 10069551
Drug: Ritanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 10 mg/day
Study: 31148099
Drug: Nimodipine 90
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 90 mg/die t.i.d plus placebo b.i.d
Study: 29142011
Drug: Mediterranean/low-carbohydrate (MED/LC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean/low-carbohydrate (MED/LC) diet + 28 g walnuts/day
Study: 7128192
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin at night
Study: 27055824
Drug: Ashwagandha (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha (300 mg) twice daily
Study: 15271690
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections (100 mg of testosterone enanthate injected weekly)
Study: 15271690
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections + Resistance training
Study: 11966550
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine (2 mg.ml(‐1))
Study: 11966550
Drug: Ropivacaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (2 mg.ml(‐1)) with sufentanil (1 microg.ml(‐1))
Study: 2092965
Drug: Urapidil (30mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (30mg, 60mg, or 90mg twice daily)
Study: 30239610
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma 25(OH)D >33.6 ng/mL
Study: 30239610
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma 25(OH)D <20 ng/mL
Study: 10420027
Drug: KTP/Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP/Nd:YAG laser treatment
Study: 31345359
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d zinc (as zinc gluconate) for 12 weeks
Study: 19739499
Drug: Biobloc appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biobloc appliance treatment
Study: 17966440
Drug: ACEI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI plus antiarrhythmic (Propafenona, 450 mg daily)
Study: 17966440
Drug: Antiarrhythmic (Propafenona,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic (Propafenona, 450 mg daily)
Study: 3302542
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered intraincisionally before surgery and immediately after surgery (total 5,250 mg)
Study: 3302542
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered only postoperatively (total 5,250 mg)
Study: 29262978
Drug: Varenicline combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline combined with nicotine replacement therapy (NRT)
Study: 22272505
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation mode condition (visual working memory)
Study: 10694308
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% emulsion-gel
Study: 3902954
Drug: Oral cholecystography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecystography (OCG)
Study: 1393414
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of US and OCG
Study: 3531310
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. for 6 weeks
Study: 21383275
Drug: School-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based care group (preventive medications administered by school nurses)
Study: 19698035
Drug: Spinal-epidural anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal-epidural anesthesia plus intravenous patient-controlled anesthesia with tramadol
Study: 19698035
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (propofol induction, maintenance with sevoflurane) plus intravenous patient-controlled anesthesia with tramadol
Study: 17904943
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (720 mL daily)
Study: 7948760
Drug: Direct Fluorescent
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Fluorescent Antibody (DFA) testing
Study: 29973252
Drug: Smartphone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-delivered cognitive behavioral therapy (CBT) components including self-monitoring, cognitive restructuring, behavioral activation, assertion training, and problem solving.
Study: 26852497
Drug: System of
Normalized name: KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: System of early diagnosis and non-pharmacological primary prevention including climatotherapeutic and physiotherapeutic methods, personalized dietary therapy, hypoxic-hypercapnic factors, and educational programs.
Study: 23546935
Drug: Delamanid-containing regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delamanid-containing regimens (treatment group)
Study: 21722684
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg CHO hepatitis B vaccine
Study: 21722684
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg CHO hepatitis B vaccine
Study: 21722684
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 10 μg and 20 μg groups
Study: 16689009
Drug: Jinghua Weikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghua Weikang Capsule (JWC), 160 mg 3 times per day, orally before meals for 4 weeks
Study: 16689009
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg twice per day, orally before meals for 4 weeks
Study: 9056005
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg intravenously (i.v.) every 8 hours (q8h)
Study: 9056005
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg orally (p.o.) every 8 hours (q8h)
Study: 9056005
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg orally (p.o.) every 12 hours (q12h)
Study: 8285777
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg/day/1.73 m2 surface area)
Study: 2957052
Drug: Provera (100-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provera (100- and 200-mg tablets)
Study: 2957052
Drug: Farlutal (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farlutal (500-mg tablets)
Study: 8628597
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg/d
Study: 8198020
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/d
Study: 12868997
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/d
Study: 11044537
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 IU daily (prophylactic dose)
Study: 11044537
Drug: Adjusted-weight dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily
Study: 8227722
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pre‐filter heparin
Study: 3955779
Drug: Ceftriaxone 2g
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 2g daily (1st trial)
Study: 3955779
Drug: Ceftriaxone 1g
Normalized name: CEFTRIAXONE 1GM/VIL/LIDOCAINE 1% INJ KIT
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 1g once daily (2nd trial)
Study: 3955779
Drug: Ceftriaxone 2g
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 2g single daily (1st trial)
Study: 30078506
Drug: Individualized adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized adjuvant treatment based on a molecular‐integrated risk profile
Study: 30078506
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant treatment; vaginal brachytherapy
Study: 26724694
Drug: Measurement-based antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement-based antidepressant management
Study: 27032074
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive medication
Study: 8678389
Drug: 5 monthly
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 monthly injections of 50 micrograms of rgp 120 in MF59
Study: 6364329
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metronidazole 2 times daily for 7 days
Study: 27050869
Drug: Testosterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (100 mg testosterone gel daily for 6 months)
Study: 27050869
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo gel daily for 6 months)
Study: 15866088
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/day)
Study: 7578653
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion followed by yohimbine 0.4 mg/kg IV
Study: 7578653
Drug: Yohimbine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 0.4 mg/kg IV alone
Study: 6782251
Drug: Intravesical thio-tepa
Normalized name: thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical thio-tepa (30 mg or 60 mg) for ablation
Study: 6782251
Drug: Intravesical thio-tepa
Normalized name: thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravesical thio-tepa (30 mg or 60 mg) for prophylaxis
Study: 17426180
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose albendazole
Study: 11465013
Drug: Fluoxetine (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (an SSRI)
Study: 9571599
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens orally for 18 days followed by a combined treatment with MPA for 10 days
Study: 7924783
Drug: Indwelling catheters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling catheters (Insuflon) for insulin injections
Study: 25738667
Drug: Hepatitis E
Normalized name: hepatitis E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis E vaccine
Study: 17418849
Drug: conjugated estrogen+CA
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated estrogen+CA 50 mg
Study: 17418849
Drug: EE+CA 52
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EE+CA 52 mg
Study: 17174226
Drug: Palm oil
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oil (60 mL, fresh and deep-fried)
Study: 17483542
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy
Study: 31421233
Drug: Consistent stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent stimulant medication use (n=53, 9%)
Study: 27583368
Drug: MVA prime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA prime, sequential gp140 protein boost (M/M/P/P)
Study: 27583368
Drug: DNA prime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime, concurrent MVA/gp140 boost (D/D/MP/MP)
Study: 11966736
Drug: IGF-I (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I (10 ng/ml)
Study: 11966736
Drug: GH (1000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (1000, 5000, or 50000 ng/ml)
Study: 11966736
Drug: GH (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (200 and 5000 ng/ml) and IGF-I (10 ng/ml) for 24 and 48 h
Study: 2205455
Drug: L-acetylcarnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (500 mg three times a day)
Study: 31809439
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral progesterone (400 mg twice daily for 3 days, then once daily until surgical abortion)
Study: 31809439
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 3 days, then once daily until surgical abortion)